Sana Biotechnology (NASDAQ:SANA) Trading Up 3.8%

Sana Biotechnology, Inc. (NASDAQ:SANA) shares rose 3.8% on Friday . The stock traded as high as $5.45 and last traded at $5.43. Approximately 43,619 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 2,619,073 shares. The stock had previously closed at $5.23.

Analysts Set New Price Targets

Several brokerages have commented on SANA. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Sana Biotechnology in a research report on Thursday, May 9th. JMP Securities increased their price target on Sana Biotechnology from $8.00 to $15.00 and gave the stock a “market outperform” rating in a report on Friday, March 1st.

Sana Biotechnology Price Performance

The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -3.60 and a beta of 1.53. The stock has a 50-day moving average price of $7.95 and a 200-day moving average price of $7.30.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02). Equities analysts forecast that Sana Biotechnology, Inc. will post -1.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of SANA. Victory Capital Management Inc. bought a new stake in Sana Biotechnology in the 4th quarter valued at about $54,000. Hartline Investment Corp bought a new position in shares of Sana Biotechnology in the first quarter worth $136,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Sana Biotechnology by 42.1% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,257 shares of the company’s stock valued at $66,000 after buying an additional 4,815 shares during the last quarter. Simplex Trading LLC boosted its holdings in shares of Sana Biotechnology by 31.3% during the fourth quarter. Simplex Trading LLC now owns 18,080 shares of the company’s stock worth $73,000 after purchasing an additional 4,313 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Sana Biotechnology by 351.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,800 shares of the company’s stock worth $93,000 after buying an additional 17,753 shares during the period. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.